Delcath Systems (DCTH) Stock
Targeted regional liver cancer treatment delivery company. Here's the price, business snapshot, and what's worth knowing about Delcath Systems in October 2026.
Delcath Systems Inc (DCTH) is a healthcare company focused on targeted regional delivery of chemotherapy to the liver. Its technology is designed to isolate the liver’s blood supply temporarily, allowing higher doses of melphalan to be administered directly to tumours while limiting systemic exposure. Investors should note the company operates in a clinical‑oriented, capital‑intensive segment where regulatory decisions, trial outcomes and reimbursement dynamics can strongly affect valuation. With a market cap of approximately $398.26M, Delcath sits at a size where financing, commercial adoption and execution risk are meaningful considerations. The stock may appeal to investors interested in specialised oncology therapies, but it carries higher risk than large diversified healthcare companies. This is educational information and not personalised financial advice; values can rise and fall and past performance is not a guide to future results.
Delcath Systems (DCTH) Stock Forecast
Analyst price target, next 12 months
$22.07
+45.8% vs today's $15.13
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Delcath Systems have a consensus 12-month target of $22.07, above the current price of $15.13.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Delcath Systems’ stock, which has a target price of $22.07, indicating growth potential.
Financial Health
Delcath Systems is generating moderate revenue and cash flow, with strong profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Targeted Oncology Approach
Delcath’s hepatic delivery tech concentrates chemotherapy in the liver, which could improve local control — though clinical and regulatory outcomes remain uncertain.
Clinical & Regulatory Focus
Trial results and approvals are key value drivers; setbacks or delays can materially affect the share price, so monitor updates closely.
Commercial & Financing Risks
Small market cap means growth depends on adoption, reimbursement and access to capital; funding needs can dilute existing holders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.